Recent experience includes:
Advised long-standing diagnostics client Novacyt S.A. in relation to its recommended takeover of Yourgene Health plc, an international integrated technologies and services business which enables the delivery of genomic medicine. Both Novacyt and Yourgene are listed on AIM and Novacyt is also listed on Euronext Growth Paris. The transaction was governed by the Takeover Code and effected by a court-sanctioned scheme of arrangement under Part 26 of the Companies Act. The takeover aligns with Novacyt's post Covid-19 strategy, which focuses on portfolio development and geographic expansion.
Advising DMS Group, a French leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry listed on Euronext, in the contribution of its medical imaging division to ASIT biotech (listed company in Belgium). The main objective of this transaction is to make ASIT a group listed on Euronext and active in medical imaging over which DMS Group would have control and which could become a world leader behind the big international medtechs.
Advised GE Healthcare on the acquisition of Zionexa. GE Healthcare is a medical technology, pharmaceutical diagnostics, and digital solutions company; Zionexa is an innovator of in-vivo oncology and neurology biomarkers that help enable more personalised healthcare.
The acquisition will enable GE Healthcare to build its precision healthcare capabilities, with a focus on solutions which support the work of oncologists, nuclear medicine specialists and other physicians involved in the treatment of cancer patients. Zionexa joins the Pharmaceutical Diagnostics business of GE Healthcare.
Individual sellers of Pathognomics Limited
Acted for the individual sellers on the sale of Pathognomics Limited, a provider of digital pathology and clinical diagnostic laboratory services to Cyted Limited. Cyted and Pathognomics had previously worked together to set up and launch diagnostic services to aid earlier detection of oesophageal cancer. Through its acquisition of Pathognomics, Cyted will have an accredited laboratory environment and digital pathology technology to enable it to expand its pipeline of novel biomarkers and AI technology.
Advised this Mumbai-listed company on a wide variety of matters, including the sale of its Domestic Formulations division to Abbott Healthcare for $3.8 billion and its acquisition and subsequent disposal of Bayer’s molecular imaging product portfolio. Also advised Piramal Enterprises Limited on the sale of Piramal Imaging SA to UK based medical imaging services provider Alliance Medical Group, part of the Life Healthcare Group.
Lansen Pharmaceutical Holdings Limited
Advised Lansen on its acquisition from Novartis AG of the rights to sell Sicorten Plus, a dermatological product, in China.
Advised BTG on various transactions including $110 million acquisition of Galil Medical, a provider of cryoablatian products for the treatment of kidney and other cancers; the $220 million acquisition of EKOS Corporation, an international vascular business, headquartered in Seattle, US; its acquisition of PneumRx, an interventional pulmonology business and its related £150 million cashbox placing and the £177m takeover of Biocompatibles plc by way of scheme of arrangement.
Advised AIM listed life sciences company TyraTech on its tender offer to shareholders following the sale of its Vamousse product to Alliance Pharma plc.
Advised NetScientific on its acquisition of EMV Capital, Rule 9 waiver and simultaneous placing.
Advised on the acquisition of Catapult Therapy TCR Limited.
Management Sellers of Health iQ
Advised the Sellers of Health iQ, a leading provider in real world data and digital solutions for healthcare and life sciences, on its sale by way of auction process to Corrona LLC, a US leader in real world evidence.
Schroder UK Public Private Trust plc (SUPP)
Advising Schroder UK Public Private Trust plc (SUPP) on an agreement for the £49 million sale of seven portfolio assets to Rosetta Capital VI, LP, an investment fund managed by the UK-based life science venture capital firm Rosetta Capital Limited.